AEGiS-ATN: Heart-Disease Risk and C-Reactive Protein

Important note: Information in this article was accurate in 2002. The state of the art may have changed since the publication date.

Heart-Disease Risk and C-Reactive Protein

AIDS TREATMENT NEWS Issue #385, November 22, 2002
John S. James

In an important study reported this month, in which almost 28,000 healthy U.S. women were followed for eight years, the level of C-reactive protein, a marker of inflammation, was a better predictor than LDL cholesterol of first heart attack or related disease(1). And there was almost no correlation between the two markers (both blood tests) -- meaning that these tests are finding different at-risk populations, and using both together would be a better predictor than using either alone. Smaller studies have already reported that high C-reactive protein was associated with heart attacks, strokes, and artery disease; the new study confirmed those findings with better data.

C-reactive protein is easy to measure, but this test is not yet generally used in clinical practice. Also, it has not been proven that interventions to reduce the inflammation will lower the risk of disease, although this appears likely. The authors conducted an earlier study(2) and recommend a larger trial of statins for this purpose.

These studies did not involve HIV. However, standard guidelines for lowering heart risk are often used in HIV treatment. And inflammation might be a greater problem in persons with HIV disease than in the general population.

The HIV community should follow this developing research (as well as other experimental tests for measuring heart risk, such as homocysteine levels). Some HIV-specific research would be easy to do -- for example, testing whether certain populations have a higher level of C- reactive protein would require only one blood sample and laboratory test from each member of a cohort. Perhaps AIDS medicine could be a leader in bringing the new information into clinical practice.

References

1. Ridker PM, Rifai N, Rose L, Buring JE, and Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. NEW ENGLAND JOURNAL OF MEDICINE. November 14, 2002; volume 347, number 20, pages 1557-1565.

2. Ridker PM, Rifai N, Clearfield M, and others. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. NEW ENGLAND JOURNAL OF MEDICINE. June 28, 2001; volume 344, pages 1959-1965.
021122
ATN38503

Copyright © 2002 - AIDS Treatment News. Permission granted for noncommercial reproduction, provided that our address and phone number are included if more than short quotations are used. Subscription lists are kept confidential. AIDS Treatment News, Subscription and Editorial Office: 1233 Locust St., 5th floor Philadelphia, PA 19107 800/TREAT-1-2 toll-free email: aidsnews@critpath.org http://www.aidsnews.org

Subscription Information: Call 800/TREAT-1-2: Businesses, Institutions, Professionals: $270/year. Includes early delivery of an extra copy by email. Nonprofit organizations: $135/year. Includes early delivery of an extra copy by email. Individuals: $120/year, or $70 for six months. Special discount for persons with financial difficulties: $54/year, or $30 for six months. If you cannot afford a subscription, please write or call. Outside North, Central, or South America, add air mail postage: $20/year, $10 for six months. Back issues available. Fax subscriptions, bulk rates, and multiple subscriptions are available; contact our office for details. Please send U.S. funds: personal check or bank draft, international postal money order, or travelers checks. VISA, Mastercard, and purchase orders also accepted. ISSN # 1052-4207

AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2002. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2002. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .